Navamedic Q2 and H1 2024: Stable growth continues and is supported by a new licensing and supply agreement
Oslo, 16 August 2024 – In first half of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 277.2 million, up 12.8 per cent from the corresponding period last year. Adjusted EBITA amounted to NOK 41.1 million compared to NOK 26.3 million in 2023. The milestone payment of NOK 22.7 million...
Dela artikeln
Taggar: navamedic, stable, growth
Läs vidare på Dagens Industri